Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Acalabrutinib and Rituximab for Elderly or Frail Patients With Previously Untreated Mantle Cell Lymphoma

NCT05004064 is registered in ClinicalTrials.gov with University College, London as lead sponsor.

NCT NCT05004064
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05004064 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Acalabrutinib and Rituximab for Elderly or Frail Patients With Previously Untreated Mantle Cell Lymphoma
Lead sponsor
University College, London
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 30, 2023
Completion date
June 8, 2028
Enrollment
48 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

mantle cell lymphoma